A systematic review of health economic models and utility estimation methods in schizophrenia

References

• Mancuso A, Specchia M, Lovato E, et al. Economic burden of schizophrenia: the European situation. A scientific literature review Agostino Mancuso. Eur J Public Health. 2014;24(suppl_2).
   Google Scholar
• Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535–1540.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Birnbaum H, Demler O, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005;58(8):668–676.
   PubMed Web of Science ®Google Scholar
• Simeone JC, Ward AJ, Rotella P, et al. An evaluation of variation in published estimates of schizophrenia prevalence from 1990─ 2013: a systematic literature review. BMC Psychiatry. 2015;15(1):193.
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia,“just the facts” 4. Clinical features and conceptualization. Schizophr Res. 2009;110(1):1–23.
   PubMed Web of Science ®Google Scholar
• Chue P, Lalonde JK. Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatr Dis Treat. 2014;10:777.
   PubMed Web of Science ®Google Scholar
• Potvin S, Pampoulova T, Mancini-Marie A, et al. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry. 2006;77(6):796–798.
   PubMed Web of Science ®Google Scholar
• Williams CL, Johnstone BM, Kesterson JG, et al. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care. 1999;37(4):AS81–AS86.
   PubMed Web of Science ®Google Scholar
• Bitter I, Fehér L, Tényi T, et al. Treatment adherence and insight in schizophrenia. Psychiatr Hung. 2015;30(1):18–26.
   PubMedGoogle Scholar
• Mancuso A, Specchia ML, Lovato E, et al. Economic burden of schizophrenia: the European situation. A scientific literature review: Agostino Mancuso. Eur J Public Health. 2014;24(suppl_2).
   Google Scholar
• Flint J, Munafò M. Schizophrenia: genesis of a complex disease. Nature. 2014;511(7510):412–413.
   PubMed Web of Science ®Google Scholar
• Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295–1310.
   PubMed Web of Science ®Google Scholar
• Heeg BM, Damen J, Buskens E, et al. Modelling approaches. Pharmacoeconomics. 2008;26(8):633–648.
   PubMed Web of Science ®Google Scholar
• H-H K, Günther OH, Angermeyer MC, et al. Utility assessment in patients with mental disorders. Pharmacoeconomics. 2009;27(5):405–419.
   PubMed Web of Science ®Google Scholar
• Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Qual Life Res. 2013;22(3):683–694.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• Hermes ED, Sokoloff DM, Stroup TS, et al. Minimum clinically important difference in the Positive and Negative Syndrome Scale using data from the CATIE Schizophrenia trial. J Clin Psychiatry. 2012;73(4):526.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261.
   PubMed Web of Science ®Google Scholar
• Mohr PE, Cheng CM, Claxton K, et al. The heterogeneity of schizophrenia in disease states. Schizophr Res. 2004;71(1):83–95.
   PubMed Web of Science ®Google Scholar
• Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci. 2005 Aug;59(4):385–394.
   PubMed Web of Science ®Google Scholar
• Yang L, Li M, Tao LB, et al. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health. 2009 Nov-Dec;12(Suppl 3):S66–S69.
   PubMed Web of Science ®Google Scholar
• Phanthunane P, Vos T, Whiteford H, et al. Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. Cost Eff Resour Alloc. 2011;9:6.
   PubMedGoogle Scholar
• Anh NQ, Linh BN, Ha NT, et al. Schizophrenia interventions in Vietnam: primary results from a cost-effectiveness study. Glob Public Health. 2015;10(Suppl 1):S21–S39.
   PubMed Web of Science ®Google Scholar
• Lin L, Zhao YJ, Zhou HJ, et al. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. Int Clin Psychopharmacol. 2016 Mar;31(2):84–92.
   PubMed Web of Science ®Google Scholar
• Lubinga SJ, Mutamba BB, Nganizi A, et al. A cost-effectiveness analysis of antipsychotics for treatment of schizophrenia in Uganda. Appl Health Econ Health Policy. 2015 Oct;13(5):493–506.
   PubMed Web of Science ®Google Scholar
• Strand KB, Chisholm D, Fekadu A, et al. Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis. Health Policy Plan. 2016 May;31(4):504–513.
   PubMed Web of Science ®Google Scholar
• Davies A, Langley PC, Keks NA, et al. Risperidone versus haloperidol: II. Cost-effectiveness. Clin Ther. 1998 Jan-Feb;20(1):196–213.
   PubMed Web of Science ®Google Scholar
• Magnus A, Carr V, Mihalopoulos C, et al. Assessing cost-effectiveness of drug interventions for schizophrenia. Aust N Z J Psychiatry. 2005 Jan-Feb;39(1–2):44–54.
   PubMed Web of Science ®Google Scholar
• Lindner LM, Marasciulo AC, Farias MR, et al. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System. Rev Saude Publica. 2009 Aug;43(Suppl 1):62–69.
   PubMedGoogle Scholar
• De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics. 2005;23(Suppl 1):35–47.
   PubMed Web of Science ®Google Scholar
• Hansen K, Francois C, Toumi M, et al. A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia. Eur J Health Econ. 2002;3(3):173–179.
   PubMedGoogle Scholar
• Wang PS, Ganz DA, Benner JS, et al. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model. J Ment Health Policy Econ. 2004 Jun;7(2):77–85.
   PubMedGoogle Scholar
• Heeg B, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics. 2005;23(Suppl 1):17–33.
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009;7:4.
   PubMedGoogle Scholar
• Dilla T, Moller J, O’Donohoe P, et al. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison. BMC Psychiatry. 2014;14:298.
   PubMed Web of Science ®Google Scholar
• Damen J, Thuresson PO, Heeg B, et al. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Appl Health Econ Health Policy. 2008;6(4):189–197.
   PubMedGoogle Scholar
• Treur M, Heeg B, Moller HJ, et al. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. BMC Health Serv Res. 2009;9:32.
   PubMed Web of Science ®Google Scholar
• Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005;23(Suppl 1):75–89.
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin. 2011 Apr;27(4):713–730.
   PubMed Web of Science ®Google Scholar
• Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. Pharmacoeconomics. 2016 Apr;34(4):363–391.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Baik SH, Reynolds CF, et al. Cost-effectiveness of medicare drug plans in schizophrenia and bipolar disorder. Am J Manag Care. 2013 Feb;19(2):e55–e63.
   PubMed Web of Science ®Google Scholar
• Davies A, Vardeva K, Loze JY, et al. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK. Curr Med Res Opin. 2008 Nov;24(11):3275–3285.
   PubMed Web of Science ®Google Scholar
• Park T, Kuntz KM. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia. Value Health. 2014 Jun;17(4):310–319.
   PubMed Web of Science ®Google Scholar
• Goren JL, Rose AJ, Smith EG, et al. The business case for expanded clozapine utilization. Psychiatr Serv. 2016 Nov 01;67(11):1197–1205.
   PubMed Web of Science ®Google Scholar
• Lecomte P, De Hert M, van Dijk M, et al. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value Health. 2000 Jan-Feb;3(1):1–11.
   PubMedGoogle Scholar
• Palmer CS, Brunner E, Ruiz-Flores LG, et al. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia. Arch Med Res. 2002 Nov-Dec;33(6):572–580.
   PubMed Web of Science ®Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004;71(1):155–165.
   PubMed Web of Science ®Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Corrigendum to “Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores”[Schizophrenia Research 71 (1)(2004) 155–165]. Schizophr Res. 2005;80(1):135–136.
   Web of Science ®Google Scholar
• Lenert LA, Rupnow MF, Elnitsky C. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health Qual Life Outcomes. 2005;3(1):57.
   PubMedGoogle Scholar
• Németh B, Molnár A, Akehurst R, et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res. 2017;6:639–648.
   PubMed Web of Science ®Google Scholar
• Thokagevistk K, Millier A, Lenert L, et al. Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations. J Mark Access Health Policy. 2016;4(1):30725.
   Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008;6(1):105.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol. 1997;17(4):298–307.
   PubMed Web of Science ®Google Scholar
• Kaya R, Colakoglu HB. Taxicab versions of some Euclidean theorems. Int J Pure Appl Math. 2006;26(1):69.
   Google Scholar
• Mehnert A, Nicholl D, Pudas H, et al. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ. 2012;15(5):844–861.
   PubMedGoogle Scholar
• Laux G, Heeg BM, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics. 2005;23(1):49–61.
   PubMed Web of Science ®Google Scholar
• Siani C, De Peretti C, Millier A, et al. Predictive models for utility from positive and negative syndrome scale clinical questionnaires for schizophrenia in the United Kingdom, France and Germany–findings for the European Schizophrenia Cohort (EuroSC). Lyon: Institut De Science Financiere ET D’Assurances; 2013.
   Google Scholar
• Hansen K, Lançon C, Toumi M. Pharmacoeconomic modelling in schizophrenia. Eur J Health Econ. 2006;7(1):19–29.
   PubMedGoogle Scholar
• Milev P, Ho BC, Arndt S, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495–506.
   PubMed Web of Science ®Google Scholar
• Barbosa CD, Balp -M-M, Kulich K, et al. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39.
   PubMed Web of Science ®Google Scholar
• McIntosh E, Luengo-Fernandez R. Economic evaluation. Part 2: frameworks for combining costs and benefits in health care. J Fam Plann Reprod Health Care. 2006;32(3):176–180.
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21.
   PubMed Web of Science ®Google Scholar
• Gosselin R, Ozgediz D, Poenaru D. A square peg in a round hole? Challenges with DALY-based “burden of disease” calculations in surgery and a call for alternative metrics. World J Surg. 2013;37(11):2507–2511.
   PubMed Web of Science ®Google Scholar
• Chisholm D, Healey A, Knapp M. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol. 1997;32(2):68–75.
   PubMed Web of Science ®Google Scholar
• Zhao FL, Xie F, Hu H, et al. Transferability of indirect cost of chronic disease: a systematic review and meta-analysis. Pharmacoeconomics. 2013;31(6):501–508.
   PubMed Web of Science ®Google Scholar
• Chong HY, Teoh SL, Wu DB, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357.
   PubMed Web of Science ®Google Scholar
• Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. Pharmacoeconomics. 2017;35(1):25–42.
   PubMed Web of Science ®Google Scholar